1
|
Ji X, Hao M, Wang Y, Kong W, Pan Z, Sun Q, Miao J. Human papillomavirus self-sampling in Asia: a systematic review. Front Microbiol 2025; 16:1540609. [PMID: 40160269 PMCID: PMC11949917 DOI: 10.3389/fmicb.2025.1540609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2024] [Accepted: 02/27/2025] [Indexed: 04/02/2025] Open
Abstract
Background Human papillomavirus (HPV) self-sampling may be an accurate and effective alternative sampling method to conventional cervical cancer screening methods. This systematic review compares the accuracy and acceptance of self-sampling to clinician sampling for HPV testing in Asia. Methods The PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health, and Web of Science databases were searched for publications published from the establishment of the database to 2023. The risk of bias was assessed using the QUADAS-2 tool for studies included in this review. All studies evaluating the accuracy and acceptance of HPV self-sampling, and agreement of self- and clinician-collected samples in Asia were included. The accuracy of each study was demonstrated through the sensitivity and specificity in diagnosing cervical intraepithelial neoplasia or cancer, as well as the detection rate of HPV. The agreement between the two sampling methods was assessed based on the detection outcomes of HPV. Acceptance was indicated by women's preferences for HPV self-sampling. Results Sixty-seven studies including 117,279 adult, female participants were included in this review. The type of HPV screening, other intervention components, study design, sample size, follow-up period, analysis method, numerical outcomes, results, and limitations were extracted from each study. The sensitivity and specificity of HPV self-sampling in detecting cervical intraepithelial neoplasia were higher than 80% and 70%, consistent with the results of HPV clinician sampling. The consistency between self-sampling and clinician-sampling was high in most studies, and the kappa value was more than 0.7. Women had high acceptance of self-sampling but expressed some concerns. Conclusion Self-sampling for HPV testing can significantly improve cervical cancer screening coverage, especially in areas with limited medical resources or reluctance to accept physician sampling. In most studies, the accuracy and acceptance of HPV self-sampling was comparable to clinician sampling. However, the diagnostic criteria and HPV detection methods still need to be adjusted due to the low sensitivity of HPV self-sampling in some studies in China and India. Targeted health education should be carried out to improve the acceptance of HPV self-sampling in women. Systematic review registration https://inplasy.com/?s=INPLASY202520107, INPLASY202520107.
Collapse
Affiliation(s)
- Xuechao Ji
- Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China
| | - Menglin Hao
- Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China
| | - Yixiao Wang
- Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China
| | - Wenzhi Kong
- Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China
| | - Zangyu Pan
- Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China
| | - Qi Sun
- Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China
| | - Jinwei Miao
- Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China
- Laboratory for Clinical Medicine, Capital Medical University, Beijing, China
| |
Collapse
|
2
|
Takahashi T, Kinoshita T, Shigemi D, Imanishi Y, Sakamoto M, Ichimiya M, Mitsunami M, Song M, Inaba K. Effect of information awareness on attitudes toward human papillomavirus vaccination intentions in Japan. Vaccine X 2025; 22:100599. [PMID: 39802325 PMCID: PMC11719379 DOI: 10.1016/j.jvacx.2024.100599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2024] [Revised: 12/08/2024] [Accepted: 12/09/2024] [Indexed: 01/16/2025] Open
Abstract
Background The Human Papillomavirus (HPV) vaccination rate among Japanese high school girls remains critically low, reflecting ongoing public apprehension and misinformation. This study explores the relationship between information presentation and attitudes toward HPV vaccination in Japan. Methods We conducted a web-based survey of female high school students aged 15 to 16 and mothers of daughters of similar age across Japan. The first screening questionnaire investigated the vaccine uptake among eligible students. The detailed questions assessing awareness of HPV vaccination information, including vaccine eligibility and its cost, effectiveness, lifetime prevalence of HPV infection, and vaccine safety, were asked to the respondents. After presenting each piece of information, we investigated how the information influenced the vaccination attitudes of unvaccinated students and mothers of unvaccinated girls. Results Data collection occurred from August 20 to August 24, 2021. Of 473 students, 68 (14.4 %) had already been vaccinated before the study. Over half of the 245 participating students were aware of vaccine eligibility and cost (68.7 %) and effectiveness (63.6 %), but fewer understood lifetime prevalence (28.7 %) and safety (45.3 %). In contrast, awareness of the same questions in 245 mothers was higher than that in the students: 90.2 %, 92.5 %, 55.4 %, and 61.1 %, respectively. Among unvaccinated students and mothers of unvaccinated girls, the intention to get vaccinated increased the most after being informed about the lifetime risks of HPV infection; 50.5 % of students and 38.8 % of mothers showed a positive attitude toward the HPV vaccination. Conclusions Bridging the awareness gap between students and mothers is crucial for improving HPV vaccination rates. The findings underscore the potential of specific, targeted information to influence vaccination intentions, particularly regarding the HPV infection rate.
Collapse
Affiliation(s)
- Takayuki Takahashi
- Department of Obstetrics and Gynecology, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo, Japan
- Minpapi Association, Tokyo, Japan
| | | | | | - Yousuke Imanishi
- Minpapi Association, Tokyo, Japan
- Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
| | - Masahiko Sakamoto
- Minpapi Association, Tokyo, Japan
- Department of Pediatrics, Saku Central Hospital, Nagano, Japan
| | - Megumi Ichimiya
- Minpapi Association, Tokyo, Japan
- Department of Prevention and Community Health, George Washington University, Washington, DC, USA
| | - Makiko Mitsunami
- Minpapi Association, Tokyo, Japan
- Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, USA
| | - Mihyon Song
- Minpapi Association, Tokyo, Japan
- Marunouchi no Mori Ladies Clinic, Tokyo, Japan
| | - Kanako Inaba
- Minpapi Association, Tokyo, Japan
- Department of Obstetrics and Gynecology, Kanto Central Hospital, Tokyo, Japan
| |
Collapse
|
3
|
Serman F, Lisembard G, Sahraoui M, Berkhout C, Rochoy M, Haro A, Calafiore M. A transversal cross-sectional study of factors related to HPV vaccination status and cancer screening participation among French women aged 25-40. BMC Cancer 2024; 24:807. [PMID: 38971725 PMCID: PMC11227699 DOI: 10.1186/s12885-024-12591-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Accepted: 07/02/2024] [Indexed: 07/08/2024] Open
Abstract
BACKGROUND In 2020, uterine cervical cancer (UCC) was the 12th most common cancer among women in France and the 4th worldwide. French health authorities wanted to increase Human Papilloma Virus (HPV) vaccination and screening rates. There were still many barriers to these measures among young women, their families, and health professionals and teachers. Between 2014 and 2019, international studies found inconsistent effects of HPV vaccination on UCC screening. In 2022, a survey was conducted among women aged 25 to 40 in the Nord-Pas-de-Calais region to assess participation 1) in HPV vaccination and its barriers, 2) in UCC screening as a function of HPV vaccination status. METHODS Data were collected using an anonymous online questionnaire distributed by QR code in 80 general practices randomly selected in the Nord-Pas-de-Calais region between January and June 2022. Results were analyzed bivariately using the Chi2 test, multivariately when numbers allowed, and in age subgroups (sensitivity analysis). RESULTS 407 complete questionnaires (for 602 participating women) were analyzed. In our sample, 41% of women aged 25 to 40 in the Nord-Pas-de-Calais region were vaccinated against HPV viruses in 2022. The risk factors for non-vaccination, after multivariable adjustment, were: the periods of eligibility for vaccination in the early days of French vaccination (2007-2012: odds ratio OR = 0.04 [95% CI, 0.02-0.09]; 2012-2017: OR = 0.5 [0.3-0.8]), information received from non-medical sources (OR = 0.3 [0.2-0.6]), and absence of information about vaccination (OR = 0.12 [0.05-0.27]). In our sample, 90% of women were screened for UCC. In bivariate analysis, women at risk of not being screened were those who were youngest, had been vaccinated against HPV, were not heterosexual, lived alone, had gynecological follow-up by their general practitioner, and did not have regular gynecological follow-up. Sensitivity analysis showed that the only risk factor significantly correlated with non-screening regardless of age group was lack of regular gynecological follow-up. CONCLUSIONS Participation in HPV vaccination and UCC screening is improved by medical education and gynecological follow-up. This multicenter study, limited by the relative youth of vaccination in France, should be repeated after 2037 to assess the possible effect of vaccination on screening.
Collapse
Affiliation(s)
- Fanny Serman
- Department of General Medicine, School of Medicine, Lille University, Lille, France.
- ULR 2694 - METRICS, Lille University, Lille, France.
| | - Gabrielle Lisembard
- Department of General Medicine, School of Medicine, Lille University, Lille, France
| | - Maxence Sahraoui
- Department of General Medicine, School of Medicine, Lille University, Lille, France
| | - Christophe Berkhout
- Department of General Medicine, School of Medicine, Lille University, Lille, France
| | | | - Anthony Haro
- Department of General Medicine, School of Medicine, Lille University, Lille, France
| | - Matthieu Calafiore
- Department of General Medicine, School of Medicine, Lille University, Lille, France
- ULR 2694 - METRICS, Lille University, Lille, France
| |
Collapse
|
4
|
Onuki M, Takahashi F, Iwata T, Nakazawa H, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Mori‐Uchino M, Kukimoto I, Fujii T, Watanabe Y, Noda K, Yoshikawa H, Yaegashi N, Matsumoto K. Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study. Cancer Sci 2023; 114:4426-4432. [PMID: 37688310 PMCID: PMC10637081 DOI: 10.1111/cas.15943] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 07/19/2023] [Accepted: 07/27/2023] [Indexed: 09/10/2023] Open
Abstract
The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was licensed in Japan in 2009. HPV vaccine effectiveness against high-grade cervical lesions has been demonstrated among young Japanese women, but evidence of its effects on invasive cervical cancer (ICC) is lacking. Using data from two different cancer registries, we compared recent trends of new ICC cases by age group using Poisson regression analysis. We also analyzed time trends in HPV16/18 prevalence among 1414 Japanese women aged <40 years newly diagnosed with ICC in the past decade. Based on the population-based cancer registry, the incidence of ICC among young women aged 20-29 years showed a significant decline from 3.6 to 2.8 per 100 000 women-years during 2016-2019, but no similar decline was observed for older age groups (p < 0.01). Similarly, using data from the gynecological cancer registry of the Japan Society of Obstetrics and Gynecology, the annual number of ICCs among women aged 20-29 years also decreased from 256 cases to 135 cases during 2011-2020 (p < 0.0001). Furthermore, a declining trend in HPV16/18 prevalence in ICC was observed only among women aged 20-29 years during 2017-2022 (90.5%-64.7%, p = 0.05; Cochran-Armitage trend test). This is the first report to suggest population-level effects of HPV vaccination on ICC in Japan. Although the declining trend in HPV16/18 prevalence among young women with ICC supports a causal linkage between vaccination and results from cancer registries, further studies are warranted to confirm that our findings are attributable to vaccination.
Collapse
Affiliation(s)
- Mamiko Onuki
- Department of Obstetrics and GynecologyShowa University School of MedicineTokyoJapan
| | - Fumiaki Takahashi
- Division of Medical Engineering, Department of Information ScienceIwate Medical UniversityYahabaJapan
| | - Takashi Iwata
- Department of Obstetrics and GynecologyKeio University School of MedicineTokyoJapan
| | - Hiroshi Nakazawa
- Department of Gynecologic OncologyHyogo Cancer CenterAkashiJapan
| | - Hideaki Yahata
- Department of Obstetrics and Gynecology, Graduate School of Medical ScienceKyushu UniversityFukuokaJapan
| | - Hiroyuki Kanao
- Department of GynecologyCancer Institute HospitalTokyoJapan
| | - Koji Horie
- Department of GynecologySaitama Cancer CenterSaitamaJapan
| | | | - Ai Nio
- Gynecology ServiceNational Hospital Organization Kyushu Cancer CenterFukuokaJapan
| | - Kazuhiro Takehara
- Department of Gynecologic OncologyNational Hospital Organization Shikoku Cancer CenterMatsuyamaJapan
| | - Shoji Kamiura
- Department of GynecologyOsaka International Cancer InstituteOsakaJapan
| | - Naotake Tsuda
- Department of Obstetrics and GynecologyKurume University School of MedicineKurumeJapan
| | - Yuji Takei
- Department of Obstetrics and GynecologyJichi Medical UniversityTochigiJapan
| | - Shogo Shigeta
- Department of Obstetrics and GynecologyTohoku University Graduate School of MedicineSendaiJapan
| | - Noriomi Matsumura
- Department of Obstetrics and GynecologyKindai University Faculty of MedicineOsakaJapan
| | - Hiroyuki Yoshida
- Department of Gynecologic OncologySaitama Medical University International Medical CenterSaitamaJapan
| | - Takeshi Motohara
- Department of Obstetrics and Gynecology, Faculty of Life SciencesKumamoto UniversityKumamotoJapan
| | - Hiroyuki Yamazaki
- Department of Obstetrics and GynecologyHokkaido University Graduate School of Medicine and Faculty of MedicineSapporoJapan
| | - Keiichiro Nakamura
- Department of Obstetrics and GynecologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
| | - Junzo Hamanishi
- Department of Gynecology and ObstetricsKyoto University Graduate School of MedicineKyotoJapan
| | - Nobutaka Tasaka
- Department of Obstetrics and Gynecology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
| | - Mitsuya Ishikawa
- Department of GynecologyNational Cancer Center HospitalTokyoJapan
| | | | - Wataru Kudaka
- Department of Obstetrics and Gynecology, Graduate School of MedicineUniversity of the RyukyusOkinawaJapan
| | - Mayuyo Mori‐Uchino
- Department of Obstetrics and Gynecology, Graduate School of MedicineThe University of TokyoTokyoJapan
| | - Iwao Kukimoto
- Pathogen Genomics CenterNational Institute of Infectious DiseasesTokyoJapan
| | - Takuma Fujii
- Department of Gynecology, School of MedicineFujita Health UniversityAichiJapan
| | - Yoh Watanabe
- Division of Obstetrics and GynecologyTohoku Medical and Pharmaceutical University Graduate School of MedicineSendaiJapan
| | | | - Hiroyuki Yoshikawa
- Department of Obstetrics and Gynecology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
| | - Nobuo Yaegashi
- Department of Obstetrics and GynecologyTohoku University Graduate School of MedicineSendaiJapan
| | - Koji Matsumoto
- Department of Obstetrics and GynecologyShowa University School of MedicineTokyoJapan
| |
Collapse
|
5
|
Kurosawa M, Sekine M, Yamaguchi M, Kudo R, Hanley SJB, Hara M, Adachi S, Ueda Y, Miyagi E, Ikeda S, Yagi A, Enomoto T. Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: real-world data. Cancer Sci 2022; 113:1435-1440. [PMID: 35100477 PMCID: PMC8990292 DOI: 10.1111/cas.15282] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 01/04/2022] [Accepted: 01/18/2022] [Indexed: 11/28/2022] Open
Abstract
In Japan, public funding for HPV vaccination began in 2010 for girls aged 13–16 years (birth cohort years 1994–1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long‐term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25–26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993–1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92–109 months). The HPV high‐risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross‐protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long‐term 9‐year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.
Collapse
Affiliation(s)
- Megumi Kurosawa
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Masayuki Sekine
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Manako Yamaguchi
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Risa Kudo
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Sharon J B Hanley
- Hokkaido University Center for Environmental and Health Sciences, Sapporo, Japan
| | - Megumi Hara
- Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - Sosuke Adachi
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Yutaka Ueda
- Departments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Etsuko Miyagi
- Department of Obstetrics and Gynecology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Sayaka Ikeda
- Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan
| | - Asami Yagi
- Departments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Takayuki Enomoto
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| |
Collapse
|
6
|
Jiang L, Wang X. The miR-133b/brefeldin A-inhibited guanine nucleotide-exchange protein 1 (ARFGEF1) axis represses proliferation, invasion, and migration in cervical cancer cells. Bioengineered 2022; 13:3323-3332. [PMID: 35048795 PMCID: PMC8973932 DOI: 10.1080/21655979.2022.2027063] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Cervical cancer is a common gynecological malignancy, and miR-133b is an abnormally expressed cervical cancer gene, which suggests that miR-133b may be involved in the occurrence and development of cervical cancer. However, the underlying mechanism is still unclear. miR-133b was overexpressed or silenced in the cervical cancer cell line C33A. Brefeldin A-inhibited guanine nucleotide-exchange protein 1 (ARFGEF1) was combined with overexpression of miR-133b in C33A cells. Cell Counting Kit-8, clone formation, and Transwell assays were performed to determine the influence of miR-133b and ARFGEF1 on clone formation, proliferation, migration, and invasion of C33A cells. The interaction between miR-133b and ARFGEF1 was verified using a luciferase reporter assay. Finally, the mRNA and protein expression of miR-133b and ARFGEF1 in the tumor and adjacent normal tissues of cervical cancer patients was detected by real-time quantitative PCR, Western blotting, and immunohistochemistry. The results indicated that miR-133b up-regulation suppressed the proliferation, invasion, migration, and clone formation abilities of C33A cells (P < 0.05). However, silence of miR-133b promoted the proliferation, invasion, and migration of C33A cells (P < 0.05). Clone formation ability of C33A cells was also elevated by miR-133b deficiency (P < 0.05). Moreover, miR-133b interacted with ARFGEF1 and repressed ARFGEF1 expression in C33A cells (P < 0.05). ARFGEF1 overexpression weakened miR-133b overexpression-mediated inhibition of proliferation, invasion, and migration of C33A cells (P < 0.05). miR-133b expression was decreased, and ARFGEF1 was up-regulated in tumor tissues of cervical cancer patients (P < 0.05). All results revealed that miR-133b suppresses cervical cancer progression by inhibiting proliferation, invasion, and migration of cervical cancer cells via targeting ARFGEF1. Thus, our study determined the mechanism of miR-133b in cervical cancer, and confirmed miR-133b/ARFGEF1 may become a potential therapeutic target for cervical cancer.
Collapse
Affiliation(s)
- Lingling Jiang
- Department of Gynaecology and Obstetrics, First People's Hospital of Wenling, Wenling, Zhejing, China
| | - Xuexin Wang
- Department of Gynaecology and Obstetrics, First People's Hospital of Wenling, Wenling, Zhejing, China
| |
Collapse
|
7
|
Miyoshi A, Ueda Y, Yagi A, Kimura T, Kobayashi E, Hiramatsu K, Nakagawa S, Kimura T. Educational intervention for women in Japan coming of age for cervical cancer screening who grew up during the suspended HPV-vaccination-program. Hum Vaccin Immunother 2021; 17:4418-4422. [PMID: 35016492 PMCID: PMC8828100 DOI: 10.1080/21645515.2021.1950503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Girls born in 2001 became eligible for subsidized HPV vaccination when they reached 12 years old in 2013, but that was the year when the Japanese MHLW suspended its official governmental recommendation for HPV vaccination. Those girls will now reach 20 years of age this year, 2021, and they will become eligible for cervical cancer screening. We report on the effects of an educational intervention with an information sheet about their current unvaccinated defenselessness for HPV and the necessity for early and repeated cervical cancer screening as a way to improve their intention to have that screening and their attitude toward HPV vaccination. Among the educated women, 75.2% had a positive intention toward having cervical cancer screening, 24.8% had a negative intention. Educational intervention can significantly promote the intention of having cervical cancer screening in women who had experienced the suspension of the MHLW's official recommendation for HPV vaccination. As a result of this simple intervention, they were more likely to think that HPV vaccination was needed for themselves.
Collapse
Affiliation(s)
- Ai Miyoshi
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yutaka Ueda
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan,CONTACT Yutaka Ueda Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka Suita, Osaka567-0871, Japan
| | - Asami Yagi
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Toshihiro Kimura
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Eiji Kobayashi
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kosuke Hiramatsu
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Satoshi Nakagawa
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Tadashi Kimura
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
8
|
Sauvageau C, Gilca V, Ouakki M, Kiely M, Coutlée F, Mathieu-Chartier S, Defay F, Lambert G. Sexual behavior, clinical outcomes and attendance of cervical cancer screening by HPV vaccinated and unvaccinated sexually active women. Hum Vaccin Immunother 2021; 17:4393-4396. [PMID: 34410872 DOI: 10.1080/21645515.2021.1961470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Concerns were raised about HPV vaccination possibly leading to riskier sexual behavior. We assessed sexual behaviors, risk of sexually transmitted infection, and attendance to cervical cancer screening by HPV vaccinated and unvaccinated young women. In this analysis, 1475 questionnaires completed by women aged 17-29 years were included. The majority of respondents (67.9%) were vaccinated against HPV. The proportion of those vaccinated decreased with age: from 93.2% in those aged 17-19 to 72.9% in those aged 20-22, and 21.8% in 23-29-year olds. A higher proportion of unvaccinated respondents had at least one sexual intercourse under the age of 15 when compared to those vaccinated (30% vs. 23%, p < .0001). The number of sexual partners during the last 12 months was similar between vaccinated and unvaccinated participants. Vaccinated participants reported more condom use (45% versus 38%; p = .0002), and less sexually transmitted infections (10% versus 28%; p < .0001), and less anogenital condylomas (2.2% vs. 11.6%; p < .0001). A screening test has been reported by 51% and 77% of vaccinated and unvaccinated participants, respectively (p < .0001). The association between vaccination status and cervical cancer screening disappeared when adjusting for participants' age. The study results consolidate the existing body of data regarding the absence of an impact of HPV vaccination on sexual behavior or use of contraceptives.
Collapse
Affiliation(s)
- Chantal Sauvageau
- Direction des Risques Biologiques et de la Santé au Travail, Institut National de Santé Publique du Québec, Montreal and Quebec, Quebec, Canada, Université Laval, Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Quebec, Quebec, Canada
| | - Vladimir Gilca
- Direction des Risques Biologiques et de la Santé au Travail, Institut National de Santé Publique du Québec, Montreal and Quebec, Quebec, Canada, Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Quebec, Quebec, Canada
| | - Manale Ouakki
- Direction des Risques Biologiques et de la Santé au Travail, Institut National de Santé Publique du Québec, Montreal and Quebec, Quebec, Canada
| | - Marilou Kiely
- Direction des Risques Biologiques et de la Santé au Travail, Institut National de Santé Publique du Québec, Montreal and Quebec, Quebec, Canada
| | - François Coutlée
- Service de Biologie Moléculaire du Département de Médecine de Laboratoire et Service d'infectiologie du Département de Médecine, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
| | | | - Fannie Defay
- Direction des Risques Biologiques et de la Santé au Travail, Institut National de Santé Publique du Québec, Montreal and Quebec, Quebec, Canada
| | - Gilles Lambert
- Direction Régionale de Santé Publique, Centre Intégré Universitaire de Santé et de Services Sociauxdu Centre-Sud-de-l'Île-de-Montréal, Direction des Risques Biologiques et de la Santé au Travail, Institut National de Santé Publique du Québec, Montreal and Quebec, Quebec, Canada
| |
Collapse
|
9
|
Gong H, Wang P, Yu M, Zhu Y, Teng L, Su Y. The Role of the Hematopoietic Cell-Specific Protein 1-Associated Protein X-1 in Human Papillomavirus 16 E2-Induced Human Cervical Squamous Carcinoma Cell Apoptosis via a Mitochondria-Dependent Pathway. Gynecol Obstet Invest 2021; 86:273-282. [PMID: 34175849 DOI: 10.1159/000515532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Accepted: 02/28/2021] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Human papillomavirus 16 (HPV 16) E2 is a transcriptional regulator that plays a key role in regulating a variety of biological responses. Hematopoietic cell-specific protein 1-related protein X-1 (HAX-1) is a mitochondrial membrane protein, and the HAX-1 gene is involved in the occurrence, growth, invasion, and metastasis of various human malignant tumors. The purpose of this study was to investigate the relationships among HPV 16 E2, the role of HAX-1 gene, and the underlying intracellular apoptotic mechanism of human cervical squamous carcinoma cells (C33a and SiHa). METHODS In this study, HAX-1 expression was examined using real-time polymerase chain reaction, Western blot, and immunohistochemical staining analysis. Apoptosis of cells was assessed by flow cytometry. The mitochondrial function was assessed by the mitochondrial copy number, reactive oxygen species (ROS) generation, the mitochondrial membrane potential (ΔΨm), and mitochondrial morphology. RESULTS Our study demonstrated that the expression of the HAX-1 gene was significantly increased in human cervical carcinoma tissues relative to noncancerous cervix tissues. HPV 16 E2 inhibited HAX-1 protein expression. Overexpression of HAX-1 increased the mitochondrial copy number, decreased the production of ROS, and maintained the integrity of the mitochondrial membrane and morphology. So, enhanced expression of the HAX-1 gene could abrogate the HPV 16 E2-induced cell apoptosis. CONCLUSION Therefore, these data support a mechanism that HAX-1 plays a crucial role in HPV 16 E2-induced human cervical squamous carcinoma cell apoptosis in a mitochondrial-dependent manner.
Collapse
Affiliation(s)
- Hui Gong
- Department of Clinical Laboratory, Nanjing Maternity and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, China
| | - Ping Wang
- Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Ming Yu
- Department of Clinical Laboratory, Cancer Hospital, Harbin Medical University, Harbin, China
| | - Yu Zhu
- Department of Clinical Laboratory, Cancer Hospital, Harbin Medical University, Harbin, China
| | - Lichen Teng
- Department of Clinical Laboratory, Cancer Hospital, Harbin Medical University, Harbin, China
| | - Yajuan Su
- Department of Clinical Laboratory, Cancer Hospital, Harbin Medical University, Harbin, China
| |
Collapse
|
10
|
Taniguchi M, Ueda Y, Yagi A, Miyoshi A, Tanaka Y, Minekawa R, Endo M, Tomimatsu T, Hirai K, Nakayama T, Kimura T. Disparity of Cervical Cancer Risk in Young Japanese Women: Bipolarized Status of HPV Vaccination and Cancer Screening. Vaccines (Basel) 2021; 9:vaccines9030280. [PMID: 33808630 PMCID: PMC8003385 DOI: 10.3390/vaccines9030280] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/01/2021] [Accepted: 03/09/2021] [Indexed: 11/29/2022] Open
Abstract
Women born between 1994 and 1999 achieved high vaccination rates for human papillomavirus (HPV); they are now reaching the age of cervical cancer screening programs in Japan. In this study, we aimed to investigate the health awareness of HPV-vaccinated and unvaccinated women and to create tailored leaflets recommending cervical cancer screening for each. Surveys on the cancer screening rates for HPV-vaccinated and unvaccinated women aged 20 and 21 have demonstrated that the rate was significantly higher (p < 0.01) in vaccinated (6.2%) than in unvaccinated women (3.1%). Next, interviews and Internet questionnaires clarified that there was a trend that vaccinated women have a better health consciousness than the unvaccinated ones, and that in unvaccinated women, their willingness to receive cervical cancer screening was significantly enhanced by the fear of developing cancer. Finally, in a prospective study, the increase in the screening rate for both vaccinated and unvaccinated groups after they read tailored leaflets, from 6.4% to 7.4% and from 3.9% to 5.1%, respectively, was not statistically significant compared to the groups provided with a standard reminder letter. Cervical cancer control measures might be enhanced by recommending cervical cancer screening in ways better tailored to HPV vaccination status.
Collapse
Affiliation(s)
- Mariko Taniguchi
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan; (M.T.); (A.Y.); (A.M.); (T.T.); (T.K.)
| | - Yutaka Ueda
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan; (M.T.); (A.Y.); (A.M.); (T.T.); (T.K.)
- Correspondence: ; Tel.: +81-668-793-351; Fax: +81-668-793-359
| | - Asami Yagi
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan; (M.T.); (A.Y.); (A.M.); (T.T.); (T.K.)
| | - Ai Miyoshi
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan; (M.T.); (A.Y.); (A.M.); (T.T.); (T.K.)
| | - Yusuke Tanaka
- Department of Obstetrics and Gynecology, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Sakai 591-8025, Osaka, Japan;
| | - Ryoko Minekawa
- Ogata Family Clinic, 2-3 Matsunouchi-cho, Ashiya 659-0094, Hyogo, Japan;
| | - Masayuki Endo
- Department of Children’s and Women’s Health, Division of Health Sciences, Graduate School of Medicine, Osaka University, 1-7, Yamadaoka, Suita 565-0871, Osaka, Japan;
| | - Takuji Tomimatsu
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan; (M.T.); (A.Y.); (A.M.); (T.T.); (T.K.)
| | - Kei Hirai
- Department of Clinical Psychology, Graduate School of Human Sciences, Osaka University, 1-2, Yamadaoka, Suita 565-0871, Osaka, Japan;
| | - Tomio Nakayama
- Center for Public Health Sciences, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku 104-0045, Tokyo, Japan;
| | - Tadashi Kimura
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan; (M.T.); (A.Y.); (A.M.); (T.T.); (T.K.)
| |
Collapse
|
11
|
Internet Survey of Awareness and Behavior Related to HPV Vaccination in Japan. Vaccines (Basel) 2021; 9:vaccines9020087. [PMID: 33503989 PMCID: PMC7910902 DOI: 10.3390/vaccines9020087] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 01/20/2021] [Accepted: 01/21/2021] [Indexed: 11/16/2022] Open
Abstract
Recommendations for HPV vaccines were suspended in 2013 due to unfounded safety fears in Japan. We aimed to clarify the differences between vaccinated and unvaccinated females in their awareness, knowledge, and behaviors toward cervical cancer, HPV vaccination and sex. Questionnaires were administered online to women aged 16 to 20. We conducted investigations for the following: awareness, knowledge, and actions for cervical cancer, HPV vaccination, and sexual activity, as well as items related to participants’ social background. The survey in 828 girls revealed three points. The first is that more than half of the surveyed Japanese girls had poor knowledge about cervical cancer screening, HPV, or HPV vaccines. The second is that those in the unvaccinated group had a particularly poor knowledge of the subject and tended to have higher sexual activity. The final is that only 0.5% of the girls experienced changes in awareness about sexual activity after vaccination. In conclusion, this is the first large-scale survey analyzing the association between HPV vaccination and sexual activity in Japanese girls. Not only do unvaccinated girls not benefit from vaccines, but they also tend to engage in high-risk sexual behavior, and thus it is even more important to provide information on the effectiveness of vaccines and the usefulness of cancer screening.
Collapse
|
12
|
Miyoshi A, Ueda Y, Yagi A, Taniguchi M, Sekine M, Enomoto T, Kimura T. Health consciousness and cervical cancer screening rates in HPV-unvaccinated girls: comparison from HPV-recommended and HPV-recommendation-suspended program periods. Hum Vaccin Immunother 2020; 17:1068-1072. [PMID: 33270496 PMCID: PMC8018379 DOI: 10.1080/21645515.2020.1830684] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
In Japan, the vast majority of females between 13 and 24 are now unvaccinated for HPV and thus unprotected from HPV-caused cervical cancer. We analyzed the differences among these unvaccinated females regarding their understanding of the HPV vaccine, its role in cervical cancer prevention, and their need for cervical cancer screening - based on whether they refused vaccination when their government's recommendation for HPV vaccination was still in effect (vaccination-recommended group) - or during the last 7 years, while the government suspension was in effect (recommendation-suspended group). The vaccination-recommended group understood more about the HPV vaccine and the best timing for HPV vaccination than the recommendation-suspended group (p < .0001 and p = .002, respectively). We found that girls in the vaccination-recommended group had more chances to talk with the family about cervical cancer and they were more afraid of acquiring the disease (p < .0001 and p < .0001, respectively). The girls in the recommendation-suspended group tended to feel more inhibited from talking about cervical cancer with friends and acquaintances (p = .0262). The cervical cancer screening rate of the vaccination-recommended group was significantly higher (p = .014).
Collapse
Affiliation(s)
- Ai Miyoshi
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yutaka Ueda
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Asami Yagi
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Mariko Taniguchi
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Masayuki Sekine
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medicine, Niigata, Japan
| | - Takayuki Enomoto
- Department of Obstetrics and Gynecology, Niigata University Graduate School of Medicine, Niigata, Japan
| | - Tadashi Kimura
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
13
|
Watanabe Y, Seto Y, Oikawa R, Nakazawa T, Furuya H, Matsui H, Hosono S, Noike M, Inoue A, Yamamoto H, Itoh F, Wada K. Mouthwash-Based Highly Sensitive Pyro-Genotyping for Nine Sexually Transmitted Human Papilloma Virus Genotypes. Int J Mol Sci 2020; 21:ijms21103697. [PMID: 32456291 PMCID: PMC7279261 DOI: 10.3390/ijms21103697] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 05/20/2020] [Accepted: 05/22/2020] [Indexed: 01/05/2023] Open
Abstract
Human papillomavirus (HPV) is a common sexually transmitted infection worldwide, which spreads via contact with infected genital, anal, and oral/pharyngeal areas (oral sex) owing to diverse manners of sexual intercourse. In this study, we devised an oral HPV detection method using mouthwash waste fluids that causes less psychological resistance to visiting the outpatient otolaryngology departments. We successfully detected only the specific unique reverse sequencing probe (using pyro-genotyping) and identified the nine genotypes of HPV targeted for vaccination by pyrosequencing the mouthwash waste fluids of non-head and neck cancer patient volunteers (n = 52). A relatively large number (11/52) of mouthwash waste fluids tested positive for HPV (21.2%; genotype 6, n = 1; 11, n = 1; 16, n = 1; and 18, n = 8). These results surpassed the sensitivity observed testing the same specimens using the conventional method (1/52, 1.9%). Our method (pyro-genotyping) was developed using nine HPV genotypes targeted for vaccination and the results were highly sensitive compared to those of the conventional method. This less expensive, high-throughput, and simple method can be used for detecting oral HPV infection with fewer socio-psychological barriers.
Collapse
Affiliation(s)
- Yoshiyuki Watanabe
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Department of Otolaryngology, Toho University Omori Medical Center, Tokyo 143-8540, Japan; (R.O.); (H.Y.); (F.I.)
- Correspondence: ; Tel.: +81-44-977-8111; Fax: +81-44-976-5805
| | - Yukiko Seto
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| | - Ritsuko Oikawa
- Department of Otolaryngology, Toho University Omori Medical Center, Tokyo 143-8540, Japan; (R.O.); (H.Y.); (F.I.)
| | - Takara Nakazawa
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| | - Hanae Furuya
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| | - Hidehito Matsui
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| | - Sachiko Hosono
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| | - Mika Noike
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| | - Akiko Inoue
- Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki 210-0806, Japan; (Y.S.); (T.N.); (H.F.); (H.M.); (S.H.); (M.N.); (A.I.)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| | - Hiroyuki Yamamoto
- Department of Otolaryngology, Toho University Omori Medical Center, Tokyo 143-8540, Japan; (R.O.); (H.Y.); (F.I.)
| | - Fumio Itoh
- Department of Otolaryngology, Toho University Omori Medical Center, Tokyo 143-8540, Japan; (R.O.); (H.Y.); (F.I.)
| | - Kota Wada
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan;
| |
Collapse
|